Clinical experience with a recombinant DNA hepatitis B vaccine.
The clinical testing of EngerixR-B, the hepatitis B vaccine produced by SmithKline Biologicals using recombinant DNA technology, started in February 1984. Since extensive pre-clinical laboratory work had established that the polypeptide (HBsAg) expressed in genetically engineered yeast cells was after purification--physically, chemically and antigenically similar to the viral surface antigen particles found in the blood of chronic carriers, the aims of the clinical trials were to compare the safety, reactogenicity, immunogenicity and protective efficacy of yeast-derived (YDV) and plasma-derived (PDV) vaccines. By September 1987, 89 studies had been initiated involving a total of 10,545 subjects aged from birth to 82 years. This extensive experience has established that the risk of hypersensitivity to yeast-derived contaminants is negligible since no hypersensitivity reaction has been observed in any vaccinee, the incidence and severity of local reactions have not increased after repeated inoculations and no anti-yeast antibodies were produced by vaccination. Reactogenicity has been comparable to that of PDV's consisting essentially of transient mild irritation at the site of injection presumably caused by the aluminium hydroxide used as adjuvant. The anti-HBs responses to YDV and PDV's were quantitatively (seroconversion rates, peak antibody levels and persistence) as well as qualitatively (epitope specificity and affinity) similar. The expected protective effect of the immune response to the vaccine was confirmed in a challenge study in chimpanzees and in vaccinated human populations (male homosexuals, institutionalized mentally retarded patients, neonates of carrier women) with historically a high infection rate.
Andre
F E
FE
Medical & Scientific Services, SmithKline Biologicals, Rixensart, Belgium.
D000328:Adult; D000368:Aged; D000956:Antigens, Viral / Q000032:analysis; D002648:Child; D002675:Child, Preschool; D000939:Epitopes; D006509:Hepatitis B / Q000517:prevention & control*; D017325:Hepatitis B Vaccines; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000302:isolation & purification; D013997:Time Factors; D014761:Viral Hepatitis Vaccines / Q000276:immunology
D000956:Antigens, Viral; D000939:Epitopes; D017325:Hepatitis B Vaccines; D011994:Recombinant Proteins; D014761:Viral Hepatitis Vaccines